<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2221300-B1" country="EP" doc-number="2221300" kind="B1" date="20140108" family-id="40644852" file-reference-id="311130" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588030" ucid="EP-2221300-B1"><document-id><country>EP</country><doc-number>2221300</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08854402-A" is-representative="YES"><document-id mxw-id="PAPP154850222" load-source="docdb" format="epo"><country>EP</country><doc-number>08854402</doc-number><kind>A</kind><date>20081107</date><lang>ZH</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140549654" ucid="CN-200710177016-A" load-source="docdb"><document-id format="epo"><country>CN</country><doc-number>200710177016</doc-number><kind>A</kind><date>20071108</date></document-id></priority-claim><priority-claim mxw-id="PPC140554025" ucid="CN-2008072983-W" load-source="docdb"><document-id format="epo"><country>CN</country><doc-number>2008072983</doc-number><kind>W</kind><date>20081107</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130529</date></intention-to-grant-date><search-report-dispatch-date><date>20111028</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989324563" load-source="ipcr">C07B  57/00        20060101ALI20130506BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324564" load-source="ipcr">C07D 311/32        20060101AFI20130506BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989619893" load-source="docdb" scheme="CPC">C07D 311/36        20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989636984" load-source="docdb" scheme="CPC">C07B  57/00        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989639622" load-source="docdb" scheme="CPC">C07D 311/32        20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132368723" lang="DE" load-source="patent-office">VERFAHREN ZUR OPTISCHEN TRENNUNG DER MISCHUNG DER OPTISCHEN ISOMERE, INSBESONDERE DES RACEMATS, VON PINOCEMBRIN</invention-title><invention-title mxw-id="PT132368724" lang="EN" load-source="patent-office">METHODS FOR RESOLUTION OF THE MIXTURE OF THE OPTICAL ISOMERS, ESPECIALLY THE RACEMATE OF PINOCEMBRIN</invention-title><invention-title mxw-id="PT132368725" lang="FR" load-source="patent-office">PROCÉDÉS DE RÉSOLUTION DU MÉLANGE D'ISOMÈRES OPTIQUES, NOTAMMENT DU RACÉMATE DE PINOCEMBRINE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919524579" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD</last-name><address><country>CN</country></address></addressbook></applicant><applicant mxw-id="PPAR919530178" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.</last-name></addressbook></applicant><applicant mxw-id="PPAR919526637" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>INST MATERIA MEDICA CAMS</last-name><address><country>CN</country></address></addressbook></applicant><applicant mxw-id="PPAR919541019" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919538529" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>WU SONG</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919525111" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>WU, SONG</last-name></addressbook></inventor><inventor mxw-id="PPAR919021208" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>WU, SONG</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919527777" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>DU GUANHUA</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919526275" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>DU, GUANHUA</last-name></addressbook></inventor><inventor mxw-id="PPAR919021213" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>DU, GUANHUA</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919508831" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>YUAN YUE</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919511150" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>YUAN, Yue</last-name></addressbook></inventor><inventor mxw-id="PPAR919021211" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>YUAN, Yue</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919528737" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>YANG QINGYUN</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919510427" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>Yang, Qingyun</last-name></addressbook></inventor><inventor mxw-id="PPAR919021212" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>Yang, Qingyun</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919537178" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>GAO MEI</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919525869" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>GAO, MEI</last-name></addressbook></inventor><inventor mxw-id="PPAR919021209" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>GAO, MEI</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919509875" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>QI YAN</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919538102" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>QI, YAN</last-name></addressbook></inventor><inventor mxw-id="PPAR919021210" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>QI, YAN</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919533709" load-source="docdb" sequence="7" format="epo"><addressbook><last-name>TONG YUANFENG</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919535619" load-source="docdb" sequence="7" format="intermediate"><addressbook><last-name>TONG, YUANFENG</last-name></addressbook></inventor><inventor mxw-id="PPAR919021214" load-source="patent-office" sequence="7" format="original"><addressbook><last-name>TONG, YUANFENG</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919530765" load-source="docdb" sequence="8" format="epo"><addressbook><last-name>WANG YUEHUA</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919532210" load-source="docdb" sequence="8" format="intermediate"><addressbook><last-name>WANG, YUEHUA</last-name></addressbook></inventor><inventor mxw-id="PPAR919021215" load-source="patent-office" sequence="8" format="original"><addressbook><last-name>WANG, YUEHUA</last-name><address><street>No.1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919021218" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.</last-name><iid>101419715</iid><address><street>No. 226, Huanghe Street</street><city>Shijiazhuang Hebei 050035</city><country>CN</country></address></addressbook></assignee><assignee mxw-id="PPAR919021217" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES</last-name><iid>100777038</iid><address><street>No. 1 Xian Nong Tan Street Xuanwu District</street><city>Beijing 100050</city><country>CN</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919021216" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Maiwald, Walter</last-name><suffix>et al</suffix><iid>100027552</iid><address><street>Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3</street><city>80335 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="CN-2008072983-W"><document-id><country>CN</country><doc-number>2008072983</doc-number><kind>W</kind><date>20081107</date><lang>ZH</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009067904-A1"><document-id><country>WO</country><doc-number>2009067904</doc-number><kind>A1</kind><date>20090604</date><lang>ZH</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549888148" load-source="docdb">AT</country><country mxw-id="DS549922336" load-source="docdb">BE</country><country mxw-id="DS549781454" load-source="docdb">BG</country><country mxw-id="DS549780558" load-source="docdb">CH</country><country mxw-id="DS549872198" load-source="docdb">CY</country><country mxw-id="DS549888149" load-source="docdb">CZ</country><country mxw-id="DS549922337" load-source="docdb">DE</country><country mxw-id="DS549872199" load-source="docdb">DK</country><country mxw-id="DS549872200" load-source="docdb">EE</country><country mxw-id="DS549866348" load-source="docdb">ES</country><country mxw-id="DS549781455" load-source="docdb">FI</country><country mxw-id="DS549781456" load-source="docdb">FR</country><country mxw-id="DS549922338" load-source="docdb">GB</country><country mxw-id="DS549872201" load-source="docdb">GR</country><country mxw-id="DS549922339" load-source="docdb">HR</country><country mxw-id="DS549888154" load-source="docdb">HU</country><country mxw-id="DS549780559" load-source="docdb">IE</country><country mxw-id="DS549922340" load-source="docdb">IS</country><country mxw-id="DS549781465" load-source="docdb">IT</country><country mxw-id="DS549872206" load-source="docdb">LI</country><country mxw-id="DS549796991" load-source="docdb">LT</country><country mxw-id="DS549888155" load-source="docdb">LU</country><country mxw-id="DS549796992" load-source="docdb">LV</country><country mxw-id="DS549797001" load-source="docdb">MC</country><country mxw-id="DS549868831" load-source="docdb">MT</country><country mxw-id="DS549781466" load-source="docdb">NL</country><country mxw-id="DS549866349" load-source="docdb">NO</country><country mxw-id="DS549780560" load-source="docdb">PL</country><country mxw-id="DS549868832" load-source="docdb">PT</country><country mxw-id="DS549781467" load-source="docdb">RO</country><country mxw-id="DS549780569" load-source="docdb">SE</country><country mxw-id="DS549868833" load-source="docdb">SI</country><country mxw-id="DS549866354" load-source="docdb">SK</country><country mxw-id="DS549797002" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63960458" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>Technical Field</u></b></heading><p id="p0001" num="0001">The present invention relates to the pharmaceutical field. Specifically, the present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, especially a pinocembrin racemate, into enantiomers with single configuration.</p><heading id="h0002"><b><u>Background Art</u></b></heading><p id="p0002" num="0002">Pinocembrin has a chemical name of 2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one. Pinocembrin is a flavanone compound having one chiral center in its chemical structure. Natural pinocembrin has a steric structure of S-configuration and a specific rotation [α]D<sup>15</sup> of -45.3 (c, 0.9, acetone as solvent). Pinocembrin can be separated from propolis as well as plants such as <i>Pinus cembra, Eucalyptus sieberi, Alnus sieboldiana</i> in a relatively low level, Accordingly, the complete synthesis thereof has been studied in the art and pinocembrin in form of racemate can be prepared in large scale (<nplcit id="ncit0001" npl-type="s"><text>DUAN Yabo, et al., Chinese Journal of Medicinal Chemistry, 16(6): 342-346, 2006</text></nplcit>).</p><p id="p0003" num="0003">Pinocembrin has one chiral carbon in its molecule and thus has a pair of enantiomers i.e., (R)-pinocembrin and (S)-pinocembrin. Natural pinocembrin is (S)-pinocembrin, but its content in plants is very low and thus can not be obtained in large scale, whereas studies on biological activities of (R)-pinocembrin are not found yet. In addition, pinocembrin has not a salt-forming acidic or basic group in its structure, so that the<!-- EPO <DP n="2"> --> optical resolution of pinocembrin can not be performed by a conventional method of forming diastereomer salts. Currently, none of other methods such as crystallization, mechanical method or selective adsorption is found suitable for the resolution.</p><p id="p0004" num="0004"><nplcit id="ncit0002" npl-type="s"><text>Lepri L. et al., Journal of Liquid Chromatography &amp; Related Technologies 22:1 (1999), pages 105-118</text></nplcit>, describes the chiral resolution of reacemic flavanones (including pinocembin) using BSA.</p><p id="p0005" num="0005">Therefore, there remains a need for a method for resolution of racemic pinocembrin to obtain a pinocembrin enantiomer with single configuration.</p><heading id="h0003"><b><u>Contents of the Invention</u></b></heading><p id="p0006" num="0006">It was found surprisingly by the inventors that a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, can be effectively resolved by using a chiral primary amine as resolving agent.</p><p id="p0007" num="0007">The present invention provides a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, comprising performing the resolution by using a chiral primary amine as resolving agent. The method comprises the following steps: (1) converting a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, into a mixture of diastereoisomer derivatives by using a chiral primary amine; (2) separating and dederivatizing the pair of diastereoisomers by utilizing their different physical properties to obtain (R)-(+)-pinocembrin and (S)-(-)-pinocembrin with optical activity. Optionally, dederivatizing the separated and purified diastereoisomers comprises hydrolization, reduction and optional purification thereof to obtain single enantiomers of pinocembrin.</p><p id="p0008" num="0008">Also disclosed is (R)-pinocembrin<!-- EPO <DP n="3"> --><!-- EPO <DP n="4"> --> obtainable from racemic pinocembrin by the method of resolution according to the present invention.</p><heading id="h0004"><b><u>Specific Models for Carrying Out the Invention</u></b></heading><p id="p0009" num="0009">In one embodiment, the present invention provides a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, comprising the following steps: (1) derivatizing the mixture of pinocembrin optical isomers to be separated to form a mixture of diastereoisomer derivatives by using a chiral primary amine in an organic solvent; (2) separating the diastereoisomer derivatives and dederivatizing the separated isomers to obtain (R)-(+)-pinocembrin and (S)-(-)-pinocembrin with optical activity.</p><p id="p0010" num="0010">The present invention is suitable for various mixtures of pinocembrin optical isomers which need to be resolved into (R)-pinocembrin and (S)-pinocembrin, in which (R)-pinocembrin and (S)-pinocembrin exist in any ratio. In one embodiment, the mixture of pinocembrin optical isomers is a racemic pinocembrin.</p><p id="p0011" num="0011">Pinocembrin may be directly derivatized by using a chiral primary amine to achieve resolution without any pre-treatment. In the present invention, the phenol hydroxyl group of pinocembrin is protected with a protective group before the derivation using the chiral primary amine, and the protective group is removed after the derivation reaction or the resolution of isomers in R-form and S-form.</p><p id="p0012" num="0012">Therefore, the phenol hydroxyl group of pinocembrin to be resolved is protected. The protective group can be benzyl, methyl, acetyl, or methoxymethyl, as well as other groups suitable for<!-- EPO <DP n="5"> --> protecting a phenol hydroxyl group known to those skilled in the art. As for these protective groups and methods for protection and deprotection, reference can be made to, for example,<nplcit id="ncit0003" npl-type="b"><text> Greene Woods, Protective Groups in Organic Synthesis, Publishing House of East China University of Science and Technology, Shanghai, 2004</text></nplcit>. In one embodiment, the protective group is a benzylation agent. Preferably, the benzylation agent is benzyl chloride or benzyl bromide. More preferably, the benzylation agent is benzyl chloride. The reaction for protection of the phenol hydroxyl group of pinocembrin may be performed at any suitable temperature. Preferably, the reaction temperature is from 0°C to 150°C, and more preferably from 60°C to 80°C. Optionally, the protection reaction is performed in the presence of a base. The base can be selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium iodide (see also the protection of the phenol hydroxyl group in Example 1), and ammonium carbonate. The amount of the base can be determined readily by those skilled in the art according to conventional technical means.</p><p id="p0013" num="0013">The term "chiral primary amine" used in the present invention refers to a primary levo- or dextro-amine with optical activity, featured with one or more chiral centers in its molecule. Representative structure formula thereof is as follows:
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="33" he="25" img-content="chem" img-format="tif"/></chemistry>
wherein,
<ul><li>R<sub>1</sub> is selected from -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub><!-- EPO <DP n="6"> --> and -CH<sub>2</sub>OH;</li><li>R<sub>2</sub> is selected from phenyl, benzyl, as well as phenyl and benzyl with a substituent on aromatic ring thereof, -CH<sub>2</sub>OH, -CH(OH)CH<sub>3</sub>, -CH(OH)C<sub>2</sub>H<sub>5</sub> and phCH(OH)-, wherein the substituent is selected from -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -NO<sub>2</sub>,-CF<sub>3</sub>, -F, -Cl, -I, -OH, -OCH<sub>3</sub>, - OC<sub>2</sub>H<sub>5</sub>, -COOCH<sub>3</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>, -CONHC<sub>2</sub>H<sub>5</sub>, -CON(CH<sub>3</sub>)<sub>2</sub> and -CONHCH(CH<sub>3</sub>)<sub>2</sub>;</li><li>R<sub>3</sub> has the same definition as those of R<sub>1</sub> and R<sub>2</sub> with the proviso that R<sub>3</sub> does not have the same structure as R<sub>1</sub> or R<sub>2</sub> does at the same time.</li></ul></p><p id="p0014" num="0014">Preferable chiral primary amine is selected from the group consisting of 1-(phenyl)ethylamine, 1-(phenyl)propylamine, 2-(phenyl)propylamine, 2-amino-1-(phenyl)-1,3-propanediol, 2-amino-1-(4-chlorophenyl)-1,3-propanediol and 2-amino-1-(4-nitrophenyl)-1,3-propanediol.</p><p id="p0015" num="0015">Among the above chiral primary amines, D- or L-α-phenylethylamine is preferred.</p><p id="p0016" num="0016">The carbonyl group of pinocembrin can be derivatized using the above chiral primary amines to form optical isomer derivatives of pinocembrin with at least two chiral centers. The chiral primary amines are commercially available or can be obtained by synthesis using various methods known in the art.<!-- EPO <DP n="7"> --></p><p id="p0017" num="0017">The chiral primary amines used in the present invention preferably are optically pure.</p><p id="p0018" num="0018">In the resolution method of the present invention, the chiral primary amine can be used in any suitable ratio to the pinocembrin mixture, especially pinocembrin racemate, to be resolved. Preferably, the molar ratio of the chiral primary amine to the pinocembrin mixture to be separated is 10:1 to 1:1, more preferably 1:1.</p><p id="p0019" num="0019">The derivation reaction of the mixture of pinocembrin optical isomers with chiral primary amine according to the present invention can be performed in any suitable organic solvent. The organic<!-- EPO <DP n="8"> --> solvent can be selected from the group consisting of methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone, dichloromethane, chloroform, petroleum ether, ethyl ether, benzene, toluene, DMF, THF and any combination thereof.</p><p id="p0020" num="0020">In the present invention, the derivation reaction of a mixture of pinocembrin optical isomers with the chiral primary amine can otherwise be performed under the catalysis of an acid, preferably a Lewis acid. Preferable Lewis acid is TiCl<sub>4</sub> or Ti(OEt)<sub>4</sub> or a combination thereof. In the derivation reaction, the Lewis acid can be used in any suitable ratio to the mixture of pinocembrin optical isomers. Preferably, the molar ratio thereof is 5:1 to 0.1:1, preferably 0.5:1. Those skilled in the art are familiar with the solvent types which can be used in the derivation reaction.</p><p id="p0021" num="0021">In one preferable embodiment of the present invention, when the reaction of step (1) is performed, a racemic pinocembrin protected with a benzyl group, a chiral primary amine and triethylamine as well as TiCl<sub>4</sub> are added in order. The reaction can be performed at 0°C and then at room temperature under stirring.</p><p id="p0022" num="0022">After the end of derivation reaction, the reactant is optionally filtered with Celite and the filter cake is washed sufficiently.</p><p id="p0023" num="0023">Once the derivation reaction is finished, the product of the derivation reaction can be separated and purified through various suitable methods.</p><p id="p0024" num="0024">Said methods can be chromatography, crystallization or extraction. In one preferable embodiment, the product of the derivation reaction is separated through chromatography, especially column chromatography. The chromatography may separate the diastereomer derivatives of pinocembrin by utilizing their different polarity to obtain a less polar<!-- EPO <DP n="9"> --> single isomer and a more polar single isomer.</p><p id="p0025" num="0025">Further, the pinocembrin optical isomer derivatives obtained in step (2) is dederivatized by using a suitable method.</p><p id="p0026" num="0026">In one embodiment, the dederivation can be achieved by a hydrolization reaction. The hydrolization reaction can be performed in an organic solvent. The organic solvent can be selected from the group consisting of methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone, dichloromethane, chloroform, petroleum ether, ethyl ether, benzene, toluene, DMF, THF and any combinations thereof. The hydrolization reaction may also be performed in the presence of an acid. The acid can be selected from an inorganic acid such as HCl, HNO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub>, HOAc or any combinations thereof, or an organic acid such as formic acid, acetic acid, propanoic acid, benzenesulfonic acid, benzoic acid, oxalic acid, chloroacetic acid, trichloroacetic acid, trifluroacetic acid or any combinations thereof. These acids may have any suitable concentrations, for example, a concentration of 1% to 20%, 5% to 15% or 7% to 13%. Preferably, the acid is HCl aqueous solution of a concentration of 10% in the hydrolization system.</p><p id="p0027" num="0027">The mixture of pinocembrin optical isomers to be resolved is protected prior to the resolution, the above protected pinocembrin optical isomers can be deprotected after the dederivation is finished. As described above, those skilled in the art know well the deprotection method of the protected phenolic hydroxyl group, which can be performed by, for example, comprising a reduction reaction. In one embodiment, the reduction reaction is performed by a hydrogenation reaction to achieve the deprotection of phenolic hydroxyl group. The hydrogenation reaction can be performed using Pd/C as catalyst.<!-- EPO <DP n="10"> --> Preferably, the molar ratio of Pd/C to the protected pinocembrin is in the range of 0.1:1 to 5:1, more preferably 0.8:1.</p><p id="p0028" num="0028">After the mixture of pinocembrin optical isomers is subjected to the resolution, the above dederivation and the deprotection, the product can be optionally purified, if desired. The method for purification is similar to those for separating and purifying the derivation reaction product of the step (1), including, for example, column chromatography or recrystallization.</p><p id="p0029" num="0029">According to one preferred embodiment of the present invention, the reaction scheme thereof is demonstrated as follows:
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="145" he="98" img-content="chem" img-format="tif"/></chemistry></p><p id="p0030" num="0030">The solvents for reactions, the eluents for column chromatography and the solvents for solidification and recrystallization used in the present invention can be selected from the group consisting of methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone, dichloromethane, chloroform, petroleum ether, ethyl ether, benzene,<!-- EPO <DP n="11"> --> toluene, DMF, THF, their aqueous solutions with various concentrations, and any combinations thereof. Of which, the solvent for protection reaction of phenolic hydroxyl group is preferably acetone; the solvent for recrystallization is preferably petroleum ether, ethyl acetate or a combination thereof; the solvent for the derivation reaction of step (1) is preferably toluene; the eluent for separating the product of the derivation reaction of step (1) is preferably petroleum ether, ethyl acetate or a combination thereof; the solvent for the hydrolization reaction of step (2) is preferably ethanol, ethyl acetate and a combination thereof, and the recrystallization reaction is preferably ethyl acetate, ethanol or a combination thereof; the solvent for the reduction reaction of step (2) is preferably DMF; and the solvent for recrystallization of the reduction product of step (2) is preferably ethanol or an aqueous solution thereof.</p><p id="p0031" num="0031">The method as provided by the present invention for the resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, is economic and simple, the product has high purity and better yield, so that the method can be used to obtain pinocembrin enantiomers with single configuration in a large scale and may boost further studies and development of pinocembrin optical isomers.</p><p id="p0032" num="0032">Additionally, a (R)-(+)-pinocembrin can be obtained by the method of resolution according to the present invention.</p><p id="p0033" num="0033">The following examples are helpful to understand the present invention, but are not intended to limit the scope of the invention.<!-- EPO <DP n="12"> --></p><p id="p0034" num="0034">The e.e. value (enantiomer excess) of pinocembrin in single configuration is measured by high performance liquid chromatography in the Examples, in which the specific parameters are as follows:
<ul><li>Shimadzu LC-10Avp-type high performance liquid chromatography; CLASS-VP chromatography data system; Chiralcel AD-RH column, 5µm, 150mmx4.6mm ID; mobile phase: methanol; flow rate: 0.5mL/min; column temperature: 20°C; detection wavelength: 290nm.</li></ul></p><heading id="h0005"><b>Examples</b></heading><heading id="h0006"><b>Example 1: Protection of pinocembrin phenolic hydroxyl group</b></heading><p id="p0035" num="0035">To 100ml acetone, 8.53g (33mmol) of a racemic pinocembrin powder (obtained according to the method of <nplcit id="ncit0004" npl-type="s"><text>DUAN Yabo et al, Chinese Journal of Medicinal Chemistry, 16(6):342-346, 2006</text></nplcit>) was added, stirred and dissolved, then 5g (36mmol) of K<sub>2</sub>CO<sub>3</sub> powder and 0.31g (1.88mmol) of KI were added thereto, stirred for 5 minutes. 5ml (43mmol) of benzyl chloride was added, heated with an oil bath to reflux and monitored by TLC until the completion of the reaction (about 4h).Then stopped heating, cooled to room temperature, inorganic salts were removed by filtration under a reduced pressure, the filter cake was washed fully with acetone, then the filtrate was collected, concentrated, and purified by a common silica gel column chromatography to give a pale yellow oil product, which was solidified with light petroleum to give a solid of benzyl protected racemic pinocembrin (10.26g, yield 89.0%).</p><heading id="h0007"><b>Example 2: Derivatization reaction and resolution</b></heading><!-- EPO <DP n="13"> --><p id="p0036" num="0036">To 100ml toluene, 19.7g (57mmol) of the benzyl protected racemic pinocembrin was added, stirred and then cooled to 0°C with an ice bath, 15ml (109mmol) of triethylamine and 7.3ml (57mmol) of L-α-methylbenzylamine were dissolved in 20ml of toluene, and the obtained mixture solution was added to the above reaction liquid, and stirred for 5 minutes. 3.25ml (29mmol) of TiCl<sub>4</sub> was dissolved in 10ml of toluene, and the obtained mixture solution was added dropwise to the reaction liquid. After 10 minutes of agitation, the ice bath was removed, and agitation was continued at room temperature. The reaction was subjected to a desiccation treatment, i.e., all instruments and reagents were dried and a N<sub>2</sub> protection was used during the reaction. The reaction was monitored by TLC until completion (about 48h). Stopped agitating, the reaction mixture was filtered through a funnel filled with enough Celite, the filter cake was washed fully with ethyl acetate, the filtrate was collected, concentrated and purified by a common silica gel column chromatography to give a less polar yellow oil product of 6.7g and a more polar yellow oil product of 7.5g (total yield was about 55.5%).</p><heading id="h0008"><b>Example 3: Dederivation of resolution product</b></heading><p id="p0037" num="0037">7.5g of the more polar yellow oil product obtained in Example 2 was dissolved in 70ml of a mixture solvent of ethyl acetate and ethanol in a ratio of 5:2 (V:V), stirred and heated to reflux with an oil bath, and 20ml of 10% aqueous HCl was added in four batches (each 5ml) with a time interval of 0.5h for each batch. The reaction was monitored by TLC until completion (about 2.5h). Then stopped heating, cooled to room temperature, the reaction mixture was extracted with ethyl acetate and water. The organic phase was collected, concentrated and recrystallized with 95% ethanol to give a white solid of benzyl protected pinocembrin<!-- EPO <DP n="14"> --> in S-configuration (4.4g) with specific rotation [α]<sub>D</sub><sup>20</sup>= -30.78° (c = 0.510, acetone).</p><heading id="h0009"><b>Example 4: Dederivation of resolution product</b></heading><p id="p0038" num="0038">6.7g of the less polar yellow oil product obtained in Example 2 was dissolved in 70ml of a mixture solution of ethyl acetate and ethanol in a ratio of 5:2(V:V), stirred and heated to reflux with an oil bath, and 20ml of 10% aqueous HCl was added in four batches (each 5ml) with a time interval of 0.5h for each batch. The reaction was monitored by TLC until completion (about 2.5h). Then stopped heating, the reaction mixture was cooled to room temperature and extracted with ethyl acetate and water. The organic phase was collected, concentrated and recrystallized with 95% ethanol to give a white solid of benzyl protected pinocembrin in R-configuration (4. 8g) with specific rotation [α]<sub>D</sub><sup>20</sup>=+30.88° (c = 0.510, acetone).</p><heading id="h0010"><b>Example 5: Deprotection of dederivation product</b></heading><p id="p0039" num="0039">4.4g of the benzyl protected pinocembrin in R-configuration obtained in Example 3 was dissolved in 100ml of DMF, 20ml of 10% aqueous HCl and 3.5g of 10% Pd-C with a water content of 62.9% were added, and then a hydrogenation at normal pressure was performed. The reaction was monitored by TLC until completion (about 5h). Then stopped stirring, the reaction mixture was filtered and extracted with ethyl acetate and water. The organic phase was collected, evaporated to remove solvent, and recrystallized with 95% ethanol to give a white solid of (S)-pinocembrin (3.0g, yield 92%) with specific rotation [α]<sub>D</sub><sup>20</sup> = -45.63° (c = 0.515, methanol), and e.e% &gt; 99.3%.</p><heading id="h0011"><b>Example 6: Deprotection of dederivation product</b></heading><!-- EPO <DP n="15"> --><p id="p0040" num="0040">4.8g of the benzyl protected pinocembrin in R-configuration obtained in Example 4 was dissolved in 100ml of DMF, 20ml of 10% aqueous HCl and 3.5g of 10% Pd-C with a water content of 62.9% were added, and then a hydrogenation at normal pressure was performed. The reaction was monitored by TLC until completion (about 5h). Then stop stirring , the reaction mixture was filtered and extracted with ethyl acetate and water. The organic phase was collected, evaporated to remove solvent and recrystallized with 95% ethanol to give a white solid of (R)-pinocembrin (3.1g, yield 90%) with specific rotation [α]<sub>D</sub><sup>20</sup> = +45.83° (c=0.515, methanol), and e.e% &gt; 99.3%.</p><p id="p0041" num="0041">Through the method of the present invention, (S)-(-)-pinocembrin with specific rotation [α]<sub>D</sub><sup>20</sup> ≤ -45.63° (c = 0.515, methanol) and (R)-(+)-pinocembrin with specific rotation [α]<sub>D</sub><sup>20</sup> ≥ +45.83° (c = 0.515, methanol) were obtained. The measurement by chiral HPLC indicated that both of the two optical isomers had an optical purity of 99.3% or more.</p></description><claims mxw-id="PCLM56984111" lang="DE" load-source="patent-office"><!-- EPO <DP n="19"> --><claim id="c-de-01-0001" num="0001"><claim-text>Ein Verfahren zur Auftrennung einer Mischung aus optischen Isomeren von Pinocembrin, speziell eines Pinocembrin-Racemats, das Verfahren umfassend die folgenden Schritte:
<claim-text>(1) Derivatisierung einer Mischung aus optischen Isomeren von Pinocembrin, die zuvor einer Reaktion zum Schutz der phenolischen Hydroxylgruppen unterzogen wurden, mit einem chiralen primären Amin, so dass eine Mischung aus Diastereomeren entsteht, und Auftrennung der Mischung von Diastereomeren sowie optional Reinigung der Diastereomere; und</claim-text>
<claim-text>(2) Entderivatisierung der aufgetrennten Diastereomere, und Entschützung, und optionale Reinigung, so dass (R)-(+)-Pinocembrin und/oder (S)-(-)Pinocembrin erhalten werden,<br/>
wobei das chirale primäre Amin durch die folgende generische Formel wiedergegeben wird:
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="39" he="26" img-content="chem" img-format="tif"/></chemistry>
chirales primäres Amin<br/>
worin
<claim-text>R<sub>1</sub> ausgewählt ist aus -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub> oder -CH<sub>2</sub>OH;<!-- EPO <DP n="20"> --></claim-text>
<claim-text>R<sub>2</sub> ausgewählt ist aus Phenyl, Benzyl, oder Phenyl oder Benzyl mit einem Substituenten am aromatischen Ring, -CH<sub>2</sub>OH-CH(OH)CH<sub>3</sub>, -CH(OH)C<sub>2</sub>H<sub>5</sub>, phCH(OH)-, wobei der Substituent ausgewählt ist aus -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; -(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -NO<sub>2</sub>, -CF<sub>3</sub>, -F, -Cl, -I, -OH, -OCH<sub>3</sub>, -OC<sub>2</sub>H<sub>5</sub>, -COOCH<sub>3</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>, -CONHC<sub>2</sub>H<sub>5</sub>, -CON(CH<sub>3</sub>)<sub>2</sub> oder CONHCH(CH<sub>3</sub>)<sub>2</sub>;</claim-text>
<claim-text>R<sub>3</sub> dieselbe Definition wie R<sub>1</sub> und R<sub>2</sub> hat unter der Bedingung, dass R<sub>3</sub> nicht gleichzeitig dieselbe Struktur wie R<sub>1</sub> oder R<sub>2</sub> hat.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Das Verfahren gemäß Anspruch 1, worin die Schutzgruppe Benzyl, Methyl, Acetyl, Methoxymethyl ist, und worin speziell die Schutzgruppenreaktion zum Schutz der phenolischen Hydroxylgruppe durchgeführt wird unter Verwendung von Benzylchlorid oder Benzylbromid.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Das Verfahren gemäß irgendeinem der Ansprüche 1 bis 2, worin die Derivatisierungsreaktion unter Katalyse einer Lewis-Säure durchgeführt wird.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Das Verfahren gemäß irgendeinem der Ansprüche 1 bis 3, worin das Molverhältnis des chiralen primären Amins zur Mischung der optischen Isomere von Pinocembrin im Bereich von 10:1 1 zu 1:1 1 liegt, vorzugsweise 1:1 ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Das Verfahren gemäß irgendeinem der Ansprüche 1 bis 4, worin das chirale primäre Amin D- oder L-α-Phenethylamin ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Das Verfahren gemäß irgendeinem der Ansprüche 1 bis 5, worin die Auftrennung oder Reinigung des Schritts (1) Kristallisierung, Extraktion oder Chromatografie ist, speziell Säulenchromatografie ist.<!-- EPO <DP n="21"> --></claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Das Verfahren gemäß irgendeinem der Ansprüche 1 bis 6, worin Schritt (2) durchgeführt wird durch Hydrolyse der Diastereomere, speziell in Gegenwart einer Säure, wobei die Säure vorzugsweise eine anorganische Säure wie HCl, HNO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub>, HOAc oder eine Kombination davon ist, speziell bevorzugt eine wässrige Lösung von HCl mit einer Konzentration von 10% im Hydrolysesystem ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Das Verfahren gemäß irgendeinem der Ansprüche 1 bis 7, worin die Entschützung der entderivatisierten Diastereomere durch eine Reduktionsreaktion erreicht wird, bevorzugt durch eine Hydrierungsreaktion unter Verwendung von Pd/C als Katalysator.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Das Verfahren gemäß Anspruch 3, worin die Lewis-Säure ausgewählt ist aus TiCl<sub>4</sub> oder Ti(OEt)<sub>4</sub> oder einer Mischung davon, und worin das Molverhältnis der Lewis-Säure zu der Mischung von optischen Isomeren von Pinocembrin bevorzugt im Bereich von 5:1 1 zu 0,1:1 1 liegt, bevorzugter 0,5:1 ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Das Verfahren gemäß Anspruch 8, worin das Molverhältnis des Pd/C zur Mischung der Diastereomere von Pinocembrin im Bereich von 0,1:1 bis 5:1 liegt, bevorzugt 0,8:1 ist.</claim-text></claim></claims><claims mxw-id="PCLM56984112" lang="EN" load-source="patent-office"><!-- EPO <DP n="16"> --><claim id="c-en-01-0001" num="0001"><claim-text>A method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, said method comprising the following steps:
<claim-text>(1) performing a derivation reaction of a mixture of pinocembrin optical isomers, which has been subjected to a phenolic hydroxyl group protection, with a chiral primary amine to provide a mixture of diastereoisomers, and performing a separation of the mixture of diastereoisomers and optionally performing a purification; and</claim-text>
<claim-text>(2) dederivatizing the separated diastereoisomers, and performing a deprotection, and optionally performing a purification, to obtain (R)-(+)-pinocembrin and/or (S)-(-)-pinocembrin,</claim-text>
wherein said chiral primary amine is represented by the following general formula:
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="42" he="29" img-content="chem" img-format="tif"/></chemistry>
chiral primary amine<br/>
wherein,
<claim-text>R<sub>1</sub> is selected from -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub> or - CH<sub>2</sub>OH;<!-- EPO <DP n="17"> --></claim-text>
<claim-text>R<sub>2</sub> is selected from phenyl, benzyl, or phenyl or benzyl with a substituent on aromatic ring thereof, -CH<sub>2</sub>OH-CH(OH)CH<sub>3</sub>, -CH(OH)C<sub>2</sub>H<sub>5</sub>, phCH(OH)-, wherein the substituent is selected from -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>,-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -NO<sub>2</sub>, -CF<sub>3</sub>, -F, -Cl, -I, -OH,-OCH<sub>3</sub>, -OC<sub>2</sub>H<sub>5</sub>, -COOCH<sub>3</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>,-CONHC<sub>2</sub>H<sub>5</sub>, -CON(CH<sub>3</sub>)<sub>2</sub> or -CONHCH(CH<sub>3</sub>)<sub>2</sub>;</claim-text>
<claim-text>R<sub>3</sub> has the same definition as those of R<sub>1</sub> and R<sub>2</sub> with proviso that R<sub>3</sub> does not have the same structure as R<sub>1</sub> or R<sub>2</sub> does at the same time.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The method according to claim 1, wherein the protective group is benzyl, methyl, acetyl, methoxymethyl, in particular, the phenolic hydroxyl group protection is performed by using benzyl chloride or benzyl bromide.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The method according to any one of claims 1 to 2, wherein the derivation reaction is performed under the catalysis of a Lewis acid.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The method according to any one of claims 1 to 3, wherein the molar ratio of the chiral primary amine to the mixture of pinocembrin optical isomers is in the range of 10:1 1 to 1:1, preferably 1:1.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The method according to any one of claims 1 to 4, wherein the chiral primary amine is D- or L-α-phenethylamine.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The method according to any one of claims 1 to 5, wherein the separation or purification of the step (1) is crystallization, extraction or chromatography, especially column chromatography.<!-- EPO <DP n="18"> --></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The method according to any one of claims 1 to 6, wherein the step (2) is performed through hydrolization of the diastereoisomers, especially in the presence of an acid, wherein the acid is preferably an inorganic acid such as HCl, HNO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub>, HOAc or a combination thereof, especially preferably a HCl aqueous solution having a concentration of 10% in the hydrolization system.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The method according to any one of claims 1 to 7, wherein the deprotection of the dederivatized diastereoisomers is performed through a reduction reaction, preferably through a hydrogenation reaction using Pd/C as catalyst.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The method according to claim 3, wherein the Lewis acid is selected from TiCl<sub>4</sub> or Ti(OEt)<sub>4</sub> or a mixture thereof, and the molar ratio of the Lewis acid to the mixture of pinocembrin optical isomers is preferably in the range of 5:1 1 to 0.1:1, more preferably 0.5:1.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The method according to claim 8, wherein the molar ratio of the Pd/C to the mixture of pinocembrin diastereoisomers is in the range of 0.1:1 to 5:1, preferably 0.8:1.</claim-text></claim></claims><claims mxw-id="PCLM56984113" lang="FR" load-source="patent-office"><!-- EPO <DP n="22"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Procédé de séparation d'un mélange d'isomères optiques de pinocembrine, en particulier un racémate de pinocembrine, ledit procédé comprenant les étapes suivantes :
<claim-text>(1) effectuer une réaction de dérivation d'un mélange d'isomères optiques de pinocembrine, qui a été soumis à une protection par un groupe hydroxyle phénolique, avec une ine primaire chirale pour donner un mélange de diastéréoisomères, et effectuer une séparation du mélange de diastéréoisomères et facultativement effectuer une purification ; et</claim-text>
<claim-text>(2) dédériver les diastéréoisomères séparés, et effectuer une déprotection, et facultativement effectuer une purification, pour obtenir de la (R)-(+)-pinocembrine et/ou de la (S)-(-)-pinocembrine,</claim-text>
dans lequel ladite amine primaire chirale est représentée par la formule générale suivante :
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="38" he="27" img-content="chem" img-format="tif"/></chemistry>
amine primaire chirale<br/>
dans laquelle,
<claim-text>R<sub>1</sub> est sélectionné parmi -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub> ou -CH<sub>2</sub>OH ;<!-- EPO <DP n="23"> --></claim-text>
<claim-text>R<sub>2</sub> est sélectionné parmi phényle, benzyle, ou phényle ou benzyle avec un substituant sur le cycle aromatique de celui-ci, -CH<sub>2</sub>OH-CH(OH)CH<sub>3</sub>, - CH(OH)C<sub>2</sub>H<sub>5</sub>, phCH(OH)- dans lequel le substituant est sélectionné parmi -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -NO<sub>2</sub>, -CF<sub>3</sub>, -F, - Cl, -I, -OH, -OCH<sub>3</sub>, -OC<sub>2</sub>H<sub>5</sub>, -COOCH<sub>3</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -CONH<sub>2</sub>, - CONHCH<sub>3</sub>, -CONHC<sub>2</sub>H<sub>5</sub>, -CON(CH<sub>3</sub>)<sub>2</sub> ou -CONHCH(CH<sub>3</sub>)<sub>2</sub> ;</claim-text>
<claim-text>R<sub>3</sub> a la même définition que celles de R<sub>1</sub> et R<sub>2</sub> à condition que R<sub>3</sub> n' ait pas la même structure que R<sub>1</sub> ou R<sub>2</sub> au même moment.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Procédé selon la revendication 1, dans lequel le groupe protecteur est un groupe benzyle, méthyle, acétyle, méthoxyméthyle, en particulier, la protection par le groupe hydroxyle phénolique est effectuée à l'aide de chlorure de benzyle ou de bromure de benzyle.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Procédé selon l'une quelconque des revendications 1 à 2, dans lequel la réaction de dérivation est effectuée lors de la catalyse d'un acide de Lewis.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Procédé selon l'une quelconque des revendications 1 à 3, dans lequel le rapport molaire entre l'amine primaire chirale et le mélange d'isomères optiques de pinocembrine se situe dans la plage de 10/1 à 1/1, est de préférence 1/1.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Procédé selon l'une quelconque des revendications 1 à 4, dans lequel l'amine primaire chirale est la D- ou la L-α-phénéthylamine.<!-- EPO <DP n="24"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la séparation ou la purification de l'étape (1) est la cristallisation, l'extraction ou la chromatographie, en particulier la chromatographie sur colonne.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Procédé selon l'une quelconque des revendications 1 à 6, dans lequel l'étape (2) est effectuée par hydrolysation des diastéréoisomères, notamment en présence d'un acide, dans lequel l'acide est de préférence un acide inorganique tel que HCl, HNO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub>, HOAc ou une combinaison de ceux-ci, de manière particulièrement préférée une solution aqueuse de HCl ayant une concentration de 10 % dans le système d'hydrolysation.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Procédé selon l'une quelconque des revendications 1 à 7, dans lequel la déprotection des diastéréoisomères dédérivés est effectuée par une réaction de réduction, de préférence par une réaction d'hydrogénation à l'aide de Pd/C en tant que catalyseur.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Procédé selon la revendication 3, dans lequel l'acide de Lewis est sélectionné parmi TiCl<sub>4</sub> ou Ti(OEt)<sub>4</sub> ou un mélange de ceux-ci, et le rapport molaire entre l'acide de Lewis et le mélange d'isomères optiques de pinocembrine se situe de préférence dans la plage de 5/1 à 0,1/1, est plus préférablement 0,5/1.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Procédé selon la revendication 8, dans lequel le rapport molaire entre le Pd/C et le mélange de diastéréoisomères de pinocembrine se situe dans la plage de 0,1/1 à 5/1, est de préférence 0,8/1.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
